Low-dose selumetinib for children with NF1 nerve tumors
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a low dose of an oral medication called selumetinib for children with NF1 who have a type of nerve tumor called a plexiform neurofibroma that cannot be removed safely by surgery. The goal is to see if the low dose can shrink or control the tumor with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NF1 by a doctor (based on standard criteria like cafe-au-lait spots, freckling, or family history).
- You have a plexiform neurofibroma tumor that was verified by a biopsy and cannot be safely removed with surgery.
- You are between 3 and 18 years old and in generally good health (normal liver, kidney, and heart function).
- You haven't taken selumetinib or similar drugs before, and you can swallow capsules whole.
- You are not currently receiving chemotherapy, radiation, or other cancer treatments for the tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests an investigational drug called smethinib (a type of targeted therapy) for people with neurofibromatosis type 1 whose tumors have grown into the brain, spine, or other important organs and cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
This trial tests a drug called selumetinib for people with a rare genetic condition called NF2-related schwannomatosis, which causes non-cancerous tumors on nerves. The study focuses on shrinking or slowing the growth of these tumors, especially those affecting hearing, and is for patients who cannot have surgery or choose not to.
Hear when a new Plexiform Neurofibromas (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.